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Objective: The primary goal was to identify the neuro­
radiological and neurophysiological risk factors for upper­
extremity hypertonia in patients with severe ischaemic su­
pratentorial stroke.
Design: Inception cohort.
Patients: Forty­three consecutive patients with an acute 
ischaemic supratentorial stroke and an initial upper­extre­
mity paralysis admitted to an academic hospital recruited 
over a 1.5­year period.
Main outcome measures: Upper­extremity hypertonia was 
assessed by the Ashworth scale and clinically relevant hy­
pertonia was defined as Ashworth scale ≥2. Any association 
of (clinically relevant) hypertonia with neuroradiological 
(lesion side, extent of lesion, and stroke history), and neuro­
physiological (motor­evoked potential and silent period) 
characteristics was investigated.
Results: Associations between hypertonia and the selected 
neuroradiological and neurophysiological risk factors were 
generally low. Univariate analyses yielded none of the select­
ed neuroradiological or neurophysiological characteristics 
as significantly associated with hypertonia. 
Conclusion: Despite the high incidence of hypertonia in 
these patients, we could not identify any of the selected neuro­
radiological or neurophysiological characteristics as a risk 
factor for hypertonia. 
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INTRODUCTION
Spasticity is a characteristic component of the upper motor 
neurone syndrome in the post-acute and chronic phases of 
stroke. The precise relationship between spasticity elicited by 
passive tendon or muscle stretch and active movement capacity, 
however, remains unclear. In the upper extremity, spasticity 
may cause difficulty with basic arm and hand abilities, such as 
reaching and grasping, as well as with many more complex ac-
tivities of daily living (ADL) (1–5). Functional effects of spas-
ticity treatment seem to depend highly on a critical selection of 
subjects, individualized goal setting, and appropriate selection 
of outcome measures (6–9). In particular, patients after severe 
stroke with a low potential for motor recovery may profit from 
a pro-active treatment approach to prevent disabling spasticity 
and the functional consequences of secondary complications, 
such as muscles stiffness, contractures and pain. Against this 
background, it seems clinically relevant to assess, besides the 
probability of motor recovery, the risk of developing spasticity 
in these patients early after stroke. 
Studies on risk factors for post-stroke spasticity are, how-
ever, scarce and complicated by the inability of clinical mea-
sures to distinguish between the neural mechanisms and the 
secondary intrinsic changes in muscle properties. Indeed, the 
clinical assessment of spasticity incorporates both neural and 
non-neural mechanisms by grading resistance against passive 
stretch (hypertonia). As for clinical risk factors, as yet, only 
modest associations of early muscle weakness and a low initial 
Barthel Index (BI) with chronic hypertonia have been found 
(10). In a companion paper describing the same selected study 
population of patients after stroke with an initial paralysis of 
the upper extremity and a BI of 0, we were unable to identify 
any clinical characteristic as an additional risk factor for early 
or persistent hypertonia, despite the high incidence of hyper-
tonia observed in these patients (11). In this perspective, it is 
a logical step to investigate whether specific neuroradiological 
or neurophysiological characteristics might be associated with 
early or persistent hypertonia. 
Neuroradiological assessments (magnetic resonance imaging 
or computerized tomography (CT) scan) in patients after acute 
stroke are performed on a routine basis to confirm diagnosis 
and differentiate lesion type. Some neuroradiological charac-
teristics (lesion type, size and site) have been associated with 
motor recovery and functional outcome, however, as yet, there 
remains much debate on whether stroke location or size are 
associated with hypertonia (12–15). Clinical heterogeneity 
with regard to both patient-groups and time post-stroke may 
be an important factor contributing to these inconsistencies 
in the literature.
Transcranial magnetic stimulation (TMS) has also become 
appreciated as a diagnostic and prognostic tool in patients after 
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stroke (16). In tonically pre-activated muscles, TMS of the 
primary motor cortex induces a short-latency motor-evoked 
potential (MEP) in the electromyogram as an excitatory effect, 
followed by a transitory suppression of the electromyographic 
activity, the silent period (SP), as an inhibitory effect (Fig. 1). 
Although motor recovery can be predicted reasonably well by 
TMS (17, 18), early prediction of hypertonia based on TMS is 
much more difficult. In patients with chronic stroke and suba-
cute stroke with focal vascular brain lesions, an association 
has been found between shortening of the SP and hypertonia 
as assessed by the Ashworth scale (AS) (19–21). Studies re-
garding these neurophysiological characteristics as potential 
risk factors for hypertonia in patients with acute stroke are, 
however, lacking.
Against this background, we conducted a prospective co-
hort study including only acute stroke patients with an initial 
paralysis of the upper extremity to maximize the likelihood 
of observing hypertonia and, thus, to optimize the chance 
of identifying additional risk factors for post-stroke upper- 
extremity hypertonia. We investigated the association of neuro-
radiological (lesion side and extent) and neurophysiological 
characteristics (MEP and SP) with early and late hypertonia, 
since these laboratory measures can be easily obtained in most 
hospitals with an acute stroke unit. 
MATERIAL AND METHODS
Patients 
As part of a larger study on the value of MEP in predicting motor 
and functional outcome after stroke (18), 43 consecutive acute pa-
tients with an ischaemic supratentorial stroke were recruited during 
a 1.5-year period. These patients were admitted to the Department of 
Neurology at the Radboud University Medical Centre Nijmegen. The 
diagnosis of stroke was made clinically by a neurologist according 
to the World Health Organization (WHO) clinical criteria (22) and 
confirmed by CT scan. 
Only patients presenting at day 1 post-stroke with no voluntary 
muscle activity and no muscle tone at the elbow, wrist or finger 
flexors (Brunnstrom stage I (23)) were included within the first 7 
days post-stroke. Patients with a poor prognosis for survival (loss of 
consciousness, severe CT abnormalities, and severe co-morbidity) as 
well as patients with severe pre-existing impairments of the upper 
extremity of any type (e.g. rheumatic deformities, contractures) were 
excluded. Patients with a history of craniotomy, epilepsy, cardiac 
prosthetic valve or pacemaker implantation, or severe polyneuropathy 
were also excluded. The local ethics committee approved the study 
protocol and written informed consent was obtained from all patients 
before study entry. 
Each patient received “best medical treatment” according to the 
guidelines of the Netherlands Society of Neurology, ensuring that each 
patient received physiotherapy to maintain optimal passive and active 
range of motion of all upper extremity joints from day 1 post-stroke. 
However, for the first 3 weeks post-stroke, no specific therapy was 
initiated aimed at facilitation of arm-hand function recovery.
Potential risk factors
Neuroradiological assessment. In each patient, a CT scan of the brain 
was made twice; the first time on the day of admission and the second 
time at week 1 post-stroke to delineate the structural lesion. Both an 
independent neuroradiologist and a neurologist (BK) assessed the 
CT scans of all patients, independently of one another. Evidence of 
previous stroke (“present” or “absent”) as well as the extent of the 
(structural) vascular lesions (“extensive” or “focal”) were recorded. 
Extensive stroke was defined as lesions with a diameter ≥5 cm and/or 
located in both subcortical and cortical areas. Stroke lesions with a 
diameter less than 5 cm and restricted to the subcortical areas (subcor-
tical white matter and/or basal ganglia and/or internal capsule) were 
regarded as focal. Both assessors were blinded with regard to the neuro-
physiological and clinical assessments. In the case of disagreement 
between the assessors, consensus was established afterwards.
Neurophysiological assessment. TMS of the motor cortex was perfor-
med twice in each patient; at first, within 1 week post-stroke (t1) and, 
secondly, at 3 weeks post-stroke (t2) by the same experienced clinical 
neurophysiologist (JP). This clinical neurophysiologist was blinded 
with regard to the results of the clinical and neuroradiological assess-
ments. Patients were positioned comfortably in a supine position. TMS 
was performed through a 90 mm circular coil placed in a tangential 
plane above the vertex and powered by a Magstim 200 magnetic sti-
mulator. The stimulus intensity was set at maximum stimulator output. 
To obtain a preferential activation of each hemisphere, a clockwise 
inducing current flow was used for the right hemisphere and a coun-
ter-clockwise current for the left hemisphere. MEPs were recorded at 
t1 and t2 from the biceps brachii muscle (BB) and the abductor digiti 
minimi muscle (ADM) on both the affected and the unaffected side. SPs 
were recorded at t1 and t2 from the ADM, as a representative muscle 
for distal motor function of the upper extremity. Recordings were made 
using an Oxford Synergy electromyograph with filter settings of 20 
Hz and 3 kHz (amplifier range 100 mV and display sensitivity of 0.5 
mV/division). A 500-millisecond post-stimulus period was analysed. 
The MEPs and SPs were preferably recorded when facilitated by a 
slight voluntary ADM contraction. When patients could not elicit a 
contraction of the affected hand muscle, they were asked to activate 
the non-paretic ADM (24). At least 2 responses were obtained to assess 
the reproducibility. The presence of a MEP was defined as any reprodu-
cible response with minimal peak-to-peak amplitude of 200 µmV. The 
absence of a positive MEP at t2 was regarded as a potential risk factor 
for post-stroke hypertonia. Responses with the highest MEP amplitude 
were used for analysis. The SP length was measured from ADM-MEP 
onset until the return of uninterrupted voluntary electromyography 
activity. Responses with the shortest SP length were used for analysis. 
Data from the non-paretic arm were compared with normative data 
and used as a reference. Finally, the BB and ADM responses (mean 
MEP amplitude and SP duration) were studied separately for both the 
paretic and the non-paretic side.
Outcome assessment
Hypertonia was clinically assessed by grading muscle tone through the 
AS (25). Muscle tone (grade 0–4) was assessed within the first 24 h 
Fig. 1. Example of a motor-evoked potential (MEP) and silent period 
(SP) in the abductor digiti minimi muscle (ADM).
9
SP right ADM: 139
SP left ADM: 150
sp
sp
MEP
J Rehabil Med 39
40 A. A. van Kuijk et al
and consecutively at weeks 1, 2, 3, 6, 12 and 26 post-stroke under 
standardized test conditions by a rehabilitation specialist (HH). The 
precise technique of assessment has been described in a companion 
paper (11). Clinically relevant hypertonia was operationally defined 
as an AS score equal to or greater than 2 in at least one joint.
Data analysis 
The MEP amplitude and SP duration obtained from the ADM and the 
BB on the paretic side were compared with the corresponding values 
obtained from the non-paretic side using Student’s t-test.
In addition, from 2×2 contingency tables, positive and negative 
predictive values for each of the potential risk factors with their 95% 
confidence interval were calculated. In case of positive outcome of 
the univariate analysis, multiple backwards logistic regression was 
planned to determine the explained variance by each characteristic 
with regard to hypertonia, independent of its possible association 
with other characteristics.
RESULTS
Neuroradiological and TMS characteristics 
Three patients were excluded from the study; 2 patients died 
within the first 2 weeks post-stroke and another patient suffered 
from a recurrent stroke at week 13 resulting in a poor prognosis 
for survival. All 3 patients continued to have a flaccid para-
lysis of the upper extremity from clinical presentation. Thus, 
40 patients, 20 women and 20 men, completed the study. The 
median age was 68 years (interquartile range 59–77 years). 
The neuroradiological characteristics of these 40 patients are 
shown in Table I. Sixteen (40%) patients had had previous 
stroke, whereas 24 (60%) patients had had a first-ever stroke. 
Twenty-nine patients had extensive lesions that were located in 
the territory of the MCA involving cortical (n=2), subcortical 
(n = 1), or both cortical and subcortical areas (n=26). Eleven 
patients had a focal, subcortically located lesion. In 4 of these 
patients the lesion was restricted to the basal ganglia. 
TMS of the motor cortex was performed in all patients, 
however, 4 patients refused the second MEP assessment. Two 
of these patients developed hypertonia, one patient within the 
first week post-stroke. In the other patient, hypertonia was 
observed from the 6th week post-stroke. Thus, the complete 
MEP data-set was available for only 36 patients. The quanti-
tative aspects of the TMS recordings are summarized in Table 
II for the subgroups of patients in which a positive MEP was 
obtained at t1 and t2. At both times, the MEP amplitudes in 
the BB and the ADM were significantly lower on the paretic 
than on the non-paretic side. 
Potential risk factors for post-stroke hypertonia
From a clinical point of view, we were most interested in 
predicting persistent hypertonia. Therefore, we considered 
hypertonia at the 26th week post-stroke as the primary out-
come. Both at t1 and at t2 no differences in MEP amplitude 
on the paretic side could be found between patients with and 
without hypertonia (Table III). At t1 no SP could be elicited 
at the paretic side in any of our patients, whereas at t2 only 
in 4 patients a SP could be determined: 2 patients with and 
2 without hypertonia. No difference in SP duration between 
these small patient groups was found. 
In univariate analyses, all associations between hypertonia 
at week 26 and the selected potential risk factors were low and 
statistically not significant (Table IV). Table IV shows the po-
sitive and negative predictive values with their 95% confidence 
intervals for all factors. The positive predictive values varied 
from 0.52 to 0.68 and the negative values from 0.36 to 0.61. 
Changing the definition of persistent hypertonia into AS ≥2 at 
the 12th week or at the 6th week post-stroke yielded similar 
results. Even if clinically relevant hypertonia was defined as 
AS ≥1, or if hypertonia at any time post-stroke was used as the 
primary outcome, no association with the selected potential 
risk factors could be demonstrated.
Table I. Neuroradiological characteristics of the 40 patients
Characteristics n
Stroke history First ever 24
Previous 16
Lesion side Left 22
Right 18
Infarct size Small (<2 cm) 1
Moderate (2–5 cm) 16
Extensive (>5 cm) 23
Infarct localization Cortical 2
Subcortical 12
Cortical/subcortical 26
Extent of stroke lesion Focal 11
Extensive 29
Table II. Transcranial magnetic stimulation characteristics for both the biceps brachii (BB) and abductor digiti minimi (ADM) muscle in patients 
obtaining a positive motor-evoked potential at week 1 and week 3 post-stroke
Paretic side
Mean (SD)
Non-paretic side
Mean (SD)
Paired sample
t-test p-value
Patients (n)
BB Amplitude Week 1 1.47 (1.27) 5.46 (5.26) 0.05 9
(mV) Week 3 1.59 (1.74) 6.11 (3.28) 0.00 15
ADM Amplitude Week 1 2.22 (1.97) 6.68 (2.52) 0.00 6
(mV) Week 3 2.28 (2.41) 7.51 (1.63) 0.00 10
Silent period Week 1 – – – 0
(msec) Week 3 336.75 (106.90) 202.50 (29.46) 0.11 4
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DISCUSSION
This study aimed to investigate to what extent selected neuro-
radiological and neurophysiological characteristics can be 
considered as risk factors for developing upper extremity 
hypertonia in patients with severe ischaemic supratentorial 
stroke. With regard to the neuroradiological assessments, the 
observed lack of association between the extent of the vascular 
lesion and hypertonia is consistent with the study of Patano et 
al. (12), who also found no correlation between lesion volume 
and muscle tone. Having had a previous stroke or the side of 
the lesion was also not significantly associated with hyper-
tonia (Table IV). In general, the lack of association between 
stroke location and hypertonia in our study may have been 
influenced by the fact that the majority of our patients suffered 
from extensive lesions on CT involving both the cortical and 
subcortical areas. In the literature, there also remains much 
debate on the influence of stroke location on the occurrence 
of hypertonia (12–15), which may well be related to the fact 
that the applied methods to localize and measure the lesions 
lack sufficient sensitivity. 
The selected neurophysiological measures obtained by TMS 
did not show a significant association with the occurrence of 
hypertonia either. Although it has been shown that muscle 
weakness is a clinical risk factor for post-stroke hypertonia, 
the absence of an ADM-MEP at the 3rd week post-stroke 
was not associated with hypertonia. This negative result can 
be explained by the fact that hypertonia may not directly 
result from damage to the corticospinal pathways, but from 
concomitant damage to the para-pyramidal pathways (26). At 
the cerebral level, there may be a loss of the cortical drive to 
several inhibitory centres in the brainstem, e.g. the origin of the 
lateral reticulospinal tract, resulting in disinhibition of bulbar 
and spinal reflexes (26–28). This loss of cortical drive may 
be due to lesions within areas projecting to the primary motor 
cortex (such as the primary somatosensory area, supplementary 
motor area, the pre-motor area, basal ganglia, thalamus and 
cerebellum. These brain areas provide important modulatory 
inputs to the primary motor cortex and lesions within these 
areas might, therefore, lead to a subsequent change in the 
balance between excitatory and inhibitory influences on the 
intra-cortical motor neurones that project to inhibitory centres 
at the level of the brainstem. Although these para-pyramidal 
pathways cannot be directly assessed, they might be indirectly 
assessed by TMS. Nevertheless, the results of this study do 
not support this clinical reasoning. 
In chronic stroke patients, Uozumi et al. (19) and Cruz-
Martinez et al. (20) found a possible association between 
TMS-induced inhibitory phenomena (SP) and hypertonia. The 
authors hypothesized that in the course of the development of 
hypertonia, cortical inhibition decreases and, subsequently, the 
SP shortens. In patients with subacute (≤2 weeks) stroke with 
a focal ischaemic lesion in the territory of the middle cerebral 
artery, Catano et al. (21) observed a decrease in SP duration 
with increasing muscle contraction. This contraction-induced 
reduction of the SP was associated with hypertonia. Although 
this (relative) inefficacy of the inhibitory mechanisms might 
be a risk factor for hypertonia, the phenomenon of contrac-
tion-induced reduction of the SP could not be assessed in our 
study. The voluntary contraction of the hand muscles in the 
majority of our patients was so severely impaired that often 
no SP could be recorded. Even patients in whom a SP could 
be elicited lacked the ability to elicit different degrees of 
voluntary contraction. As a result, in only 4 out of 40 patients 
(10%) a SP could be determined at 3 weeks post-stroke. The 
Table III. Transcranial magnetic stimulation characteristics in both the biceps brachii (BB) and abductor digiti minimi (ADM) muscle at week 1 
and at week 3 post-stroke in relation to hypertonia
Patients with hypertonia Patients without hypertonia Independent sample
n n t-test p-value
BB Amplitude (mV) Mean (SD) Week 1 1.20 (1.31) 7 2.40 (0.71) 2 0.266
Week 3 1.11 (1.44) 10 2.56 (2.04) 5 0.132
ADM Amplitude (mV) Mean (SD) Week 1 2.15 (2.10) 4 2.35 (2.48) 2 0.921
Week 3 2.28 (2.91) 6 2.27 (1.50) 4 0.993
Silent period length (msec) Week 1 – 0 – 0 –
Week 3 327.00†
487.00†
2 237.00†
296.00†
2 *
*Not calculated; †: individual data (data per patient) at week 3.
Table IV. Associations between potential risk factors and hypertonia 
(HT) at 26 weeks post-stroke
With HT 
(n)
Without HT 
(n)
PPV and NPV (95% CI)
Lesion side
Left 15 7 PPV 0.68 (0.49–0.88)
Right 7 11 NPV 0.61 (0.39–0.84)
Previous stroke
Present 14 10 PPV 0.58 (0.38–0.78)
Absent 8 8 NPV 0.50 (0.25–0.75)
Extensive stroke
Present 15 14 PPV 0.52 (0.34–0.71)
Absent 7 4 NPV 0.36 (0.03–0.69)
ADM – MEP 
at week 3
Absent 18 12 PPV 0.60 (0.43–0.78)
Present 4 6 NPV 0.60 (0.30–0.90)
ADM – MEP: abductor digiti minimi – motor evoked potential; 
PPV: positive predictive values; NPV: negative predictive values; 
CI: confidence interval.
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mean duration of the SP in 2 patients with hypertonia did not 
differ from the mean SP duration in 2 other patients without 
hypertonia. However, due to these small numbers of patients, 
the finding that the SP was not related to hypertonia in this 
acute-phase study must be interpreted with care.
It is important to note that this study was restricted to a 
homogeneous group of patients with acute stroke with initial 
paralysis of the upper extremity and a BI of 0. Predicting 
hypertonia using neuroradiological and neurophysiological 
characteristics as potential risk factors in such a severe sub-
group restricts generalization of the outcomes to less severely 
affected patients. Moreover, this severe subgroup is probably 
not the most appropriate group to study the value of TMS- 
induced inhibitory phenomena. These patients lack the ability 
to move their affected limb voluntarily and selectively, which 
is necessary to generate a MEP and a subsequent SP. 
Another possible limitation of this study may still be a lack of 
power due to the limited number of patients. We included only 
patients with initial paralysis to optimize the risk of post-stroke 
hypertonia (approximately 62%). This subgroup comprises 
however, only 19–30% of the stroke population at large (29). 
As a result, the inclusion rate was relatively low in just one 
academic hospital. Still, 40 patients should be a sufficient num-
ber to distinguish a “moderate” from an “absent” association 
between hypertonia and any clinical determinant (setting a 
at 0.05 and 1-b at 0.80). Larger studies of high-risk patients 
are needed to identify “weaker”, but significant, associations.
In conclusion, as yet, the association of neuroradiological 
stroke characteristics as well as TMS-induced excitatory and 
inhibitory phenomena with hypertonia seems to be weak, even 
in patients with severe stroke with upper extremity paralysis. In 
addition, TMS characteristics, such as the contraction-induced 
inhibition of the SP, are not applicable in these patients during 
the acute and subacute phases post-stroke.
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